• Tuesday, March 26, 2024 @ 12:00 am

FY 2023 revenue surprised positively with a cash runway well into 2025, beyond major value inflection points. Substantial upside should be unlocked upon positive “Study 008A” results in non-TRS, a partnering deal with a CNS player and starting “Study 017” trial in TRS.

Key catalysts include:

  1. Results “Study 008A” of evenamide in non-TRS (April 2024)
  2. Partnering evenamide with a major CNS player (before starting “Study 017”)
  3. Start pivotal “Study 017” trial of evenamide in TRS (Q3 2024)

Newron Valuation Report